Spots Global Cancer Trial Database for ca125
Every month we try and update this database with for ca125 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | NCT01616303 | Ovarian Neoplas... | Carboplatin Paclitaxel oregovomab | 18 Years - 75 Years | Quest PharmaTech Inc. | |
| Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer | NCT04826029 | Advanced Stage ... Advanced Stage ... Advanced Stage ... | Standard strate... Follow-up strat... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Ovarian Cancer Risk Estimation in Patients With Pelvic Mass | NCT00987649 | Adnexal Mass Ovarian Cancer | 18 Years - | Fujirebio Diagnostics, Inc. | ||
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT02948426 | Fallopian Tube ... Ovarian Cancer Primary Periton... | Autologous Mono... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding | NCT04867109 | Endometrial Neo... Postmenopause Uterine Hemorrh... Cancer Biomarke... CA 125 Antigen | Patients with P... CA125 and HE4 a... | 18 Years - | Nantes University Hospital | |
| Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer | NCT04826029 | Advanced Stage ... Advanced Stage ... Advanced Stage ... | Standard strate... Follow-up strat... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| HE4 as a Relapse Biomarker in Ovarian Cancers | NCT02595281 | Ovarian Carcino... | Experimental ar... | 18 Years - | Institut de Cancérologie de Lorraine | |
| Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis | NCT03193671 | Ovarian Neoplas... Diagnoses Disea... Biomarkers Algorithms | Diagnosis | 18 Years - | Göteborg University | |
| Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer | NCT04826029 | Advanced Stage ... Advanced Stage ... Advanced Stage ... | Standard strate... Follow-up strat... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | NCT05311579 | Ovarian Carcino... Survival Outcom... Adverse Events Niraparib Anlotinib CA125 Chemotherapy Targeted Therap... Recurrent Ovari... | Niraparib plus ... | 18 Years - | Peking Union Medical College Hospital | |
| Transforming Ovarian Cancer Diagnostic Pathways | NCT06129968 | Ovarian Cancer | - | Sandwell & West Birmingham Hospitals NHS Trust | ||
| HE4 as a Relapse Biomarker in Ovarian Cancers | NCT02595281 | Ovarian Carcino... | Experimental ar... | 18 Years - | Institut de Cancérologie de Lorraine | |
| Ovarian Cancer Risk Estimation in Patients With Pelvic Mass | NCT00987649 | Adnexal Mass Ovarian Cancer | 18 Years - | Fujirebio Diagnostics, Inc. | ||
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | NCT01616303 | Ovarian Neoplas... | Carboplatin Paclitaxel oregovomab | 18 Years - 75 Years | Quest PharmaTech Inc. | |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Clinical Trial for Ovarian Cancer (OvaRex®) | NCT00050375 | Ovarian Cancer | oregovomab | 18 Years - | Unither Pharmaceuticals | |
| Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis | NCT03193671 | Ovarian Neoplas... Diagnoses Disea... Biomarkers Algorithms | Diagnosis | 18 Years - | Göteborg University | |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
